A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

This study tests two experimental drugs — APG-115 and APG-2575 — either alone or together, for people with certain blood cancers that have come back or stopped responding to previous treatments. These drugs target proteins that help cancer cells survive. **You may be eligible if...** - You are 18 years or older - You have T-cell prolymphocytic leukemia (T-PLL) that has relapsed or is no longer responding to treatment - Or you have a type of non-Hodgkin lymphoma (NHL) that has relapsed, is not responding to treatment, or you cannot tolerate standard therapies - You are in reasonable overall health (able to perform daily activities) **You may NOT be eligible if...** - You have active, uncontrolled infections - You have serious heart conditions - You have had certain prior treatments that would disqualify participation - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.